Molecular Pharmacology Program
The Karuna Ganesh Lab
Metastasis causes >90% of cancer death. The emergence, persistence, therapy resistance and lethality of metastatic cancer is driven by dynamic and tenacious metastasis stem cells (MetScs). The Ganesh lab focuses on understanding the molecular mechanisms that underlie the emergence of regenerative plasticity during metastasis. We employ cutting edge patient-derived organoid and mouse models of colorectal cancer, transcriptomic, epigenomic and single cell approaches, and mechanistic studies to: (1) elucidate how tumor invasion and dissemination induce phenotypic plasticity enabling the emergence of pro-metastatic regenerative traits (2) dissect the role of stromal cells, including immune cells, in promoting and constraining MetSC plasticity (3) define key signaling nodes that drive MetSC plasticity and develop therapeutic strategies for targeting such vulnerabilities and (4) collaborate with clinicians to understand mechanisms of therapy resistance in metastasis.
Segal NH, Cercek A, Ku G, Wu AJ, Rimner A, Khalil DN, Reidy-Lagunes D, Cuaron J, Yang TJ, Weiser MR, Romesser PB, Stadler ZK, Varghese AM, Ganesh K, Yaeger R, Connell LC, Faleck D, Abou-Alfa GK, Mcauliffe KC, Vaiskauskas P, Solter ML, Ogle M, Adamow MJ, Holland A, Vedantam P, Wong P, Merghoub T, Vakiani E, Hollmann TJ, Juluru K, Chou JF, Capanu M, Erinjeri J, Solomon S, Yamada Y, Kemeny N, Crane CH, Saltz LB. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Apr 15;27(8):2200-2208. doi: 10.1158/1078-0432.CCR-20-2474. Epub 2021 Jan 27.
Latham A, Shia J, Patel Z, Reidy-Lagunes DL, Segal NH, Yaeger R, Ganesh K, Connell L, Kemeny NE, Kelsen DP, Hechtman JF, Nash GM, Paty PB, Zehir A, Tkachuk KA, Sheikh R, Markowitz AJ, Mandelker D, Offit K, Berger MF, Cercek A, Garcia- Aguilar J, Saltz LB, Weiser MR, Stadler ZK. Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. Clin Cancer Res. 2021 Mar 1;27(5):1429-1437. doi: 10.1158/1078-0432.CCR-20-2892. Epub 2020 Nov 16. PMCID: PMC7925361.
Karuna Ganesh, MD, PhD
- Physician-scientist Karuna Ganesh studies stem cell plasticity in metastasis, therapy resistance and tissue regeneration.
- MD, PhD, University of Cambridge (UK)
- Josie Robertson Investigator (2019-2024)
- Damon Runyon Clinical Investigator Award (2019)
- Burroughs Wellcome Career Award for Medical Scientists (2019)
- NIH/NCI K08 Clinician Scientist Career Development Award (2018)
- Investigator, Stand Up to Cancer Colorectal Cancer Dream Team (2017)
- American Cancer Society Postdoctoral Fellowship (2017)
- Shulamit Katzman Endowed Postdoctoral Fellowship (2017)
- Conquer Cancer Foundation of ASCO Young Investigator Award (2016)
- AACR Basic Cancer Research Fellowship (2016)
- MRC-LMB PhD Scholarship (2006)
- Gates Cambridge Scholarship (2004)
Lab News & Events
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Karuna Ganesh discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.